Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial

BACKGROUND: Of the more than 1.1 million men diagnosed worldwide annually with prostate cancer, the majority have indolent tumors. Distinguishing between aggressive and indolent cancer is an important clinical challenge. The current approaches for assessing tumor aggressiveness are recognized as ins...

Descripción completa

Detalles Bibliográficos
Autores principales: Peabody, John W., DeMaria, Lisa M., Tamondong-Lachica, Diana, Florentino, Jhiedon, Czarina Acelajado, M., Ouenes, Othman, Richie, Jerome P., Burgon, Trever
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496184/
https://www.ncbi.nlm.nih.gov/pubmed/28673277
http://dx.doi.org/10.1186/s12894-017-0243-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496184/
https://www.ncbi.nlm.nih.gov/pubmed/28673277
http://dx.doi.org/10.1186/s12894-017-0243-1

Ejemplares similares